Last 625.60 INR
Change Today 0.00 / 0.00%
Volume 0.0
SUNP On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

sun pharmaceutical indus (SUNP) Snapshot

Open
616.50
Previous Close
619.95
Day High
635.00
Day Low
616.50
52 Week High
03/3/14 - 653.35
52 Week Low
06/13/13 - 457.85
Market Cap
1.3T
Average Volume 10 Days
5.0M
EPS TTM
14.43
Shares Outstanding
2.1B
EX-Date
09/19/13
P/E TM
43.3x
Dividend
2.50
Dividend Yield
0.40%
Current Stock Chart for SUN PHARMACEUTICAL INDUS (SUNP)

Related News

No related news articles were found.

sun pharmaceutical indus (SUNP) Related Businessweek News

View More BusinessWeek News

sun pharmaceutical indus (SUNP) Details

Sun Pharmaceutical Industries Limited, a specialty pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients(APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as psychiatry, neurology, cardiology, diabetology, nephrology, gastroenterology, antiasthamatic and antiallergic, musculo-skeletal and pain, gynaecology and urology, orthopedics, and ophthalmology. It also provides APIs, such as anticancers, peptides, sex hormones, and controlled substances. The company was founded in 1983 and is based in Mumbai, India.

Founded in 1983

sun pharmaceutical indus (SUNP) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: 20.1M
Whole-Time Director, Chairman of Committee of...
Total Annual Compensation: 20.1M
Whole-Time Director and Member of Committee o...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2013.

sun pharmaceutical indus (SUNP) Key Developments

Sun Pharmaceutical Industries Limited Reports Earnings Results for the First Nine Months of 2014

Sun Pharmaceutical Industries Limited reported earnings results for the first nine months of 2014. The company's revenue surged up 46.5% during the first nine months of 2014 fiscal while net profit of the company was dropped 19% due to a $550 million patent infringement settlement with US drug maker Pfizer.

Sun Pharmaceutical Industries Limited, Board Meeting, Apr 06, 2014

Sun Pharmaceutical Industries Limited, Board Meeting, Apr 06, 2014. Agenda: To approve the scheme of arrangement between Ranbaxy Laboratories Limited and the Company; and to recommend the share exchange ratio of 8 fully paid up equity shares of INR 1 each of the Company for every 10 equity shares of INR 5 each of Ranbaxy Laboratories Limited.

Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Limited - M&A Call

To discuss the definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUNP:IN 625.60 INR +5.65

SUNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $38.26 USD -0.18
Cipla Ltd/India 399.05 INR +2.55
Dr Reddy's Laboratories Ltd 2,566 INR +13.30
Endo International PLC $62.02 USD +0.49
Lupin Ltd 986.70 INR +4.10
View Industry Companies
 

Industry Analysis

SUNP

Industry Average

Valuation SUNP Industry Range
Price/Earnings 49.9x
Price/Sales 8.6x
Price/Book 8.0x
Price/Cash Flow 43.6x
TEV/Sales 7.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUN PHARMACEUTICAL INDUS, please visit www.sunpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.